{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:17:34Z","timestamp":1767143854094,"version":"build-2238731810"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Salix Pharmaceuticals, a division of Bausch Health US, LLC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s40266-021-00850-w","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:05:16Z","timestamp":1617149116000},"page":"503-511","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Influence of Age on Central Effects of Methylnaltrexone in Patients with Opioid-Induced Constipation"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7552-8729","authenticated-orcid":false,"given":"Solomon S.","family":"Liao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal E.","family":"Slatkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Stambler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,31]]},"reference":[{"issue":"1","key":"850_CR1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1526-4637.2008.00495.x","volume":"10","author":"TJ Bell","year":"2009","unstructured":"Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med. 2009;10(1):35\u201342.","journal-title":"Pain Med."},{"issue":"12","key":"850_CR2","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1111\/j.1365-2036.2008.03689.x","volume":"27","author":"SF Cook","year":"2008","unstructured":"Cook SF, Lanza L, Zhou X, Sweeney CT, Goss D, Hollis K, et al. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Aliment Pharmacol Ther. 2008;27(12):1224\u201332.","journal-title":"Aliment Pharmacol Ther."},{"key":"850_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2147\/PPA.S78042","volume":"11","author":"JV Pergolizzi Jr","year":"2017","unstructured":"Pergolizzi JV Jr, Raffa RB, Pappagallo M, Fleischer C, Pergolizzi J 3rd, Zampogna G, et al. Peripherally acting mu-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy. Patient Prefer Adherence. 2017;11:107\u201319.","journal-title":"Patient Prefer Adherence."},{"issue":"25","key":"850_CR4","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1310246","volume":"370","author":"WD Chey","year":"2014","unstructured":"Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014;370(25):2387\u201396.","journal-title":"N Engl J Med."},{"issue":"8","key":"850_CR5","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s40266-016-0381-2","volume":"33","author":"S Chokhavatia","year":"2016","unstructured":"Chokhavatia S, John ES, Bridgeman MB, Dixit D. Constipation in elderly patients with noncancer pain: focus on opioid-induced constipation. Drugs Aging. 2016;33(8):557\u201374.","journal-title":"Drugs Aging."},{"issue":"1","key":"850_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/ajg.2011.349","volume":"107","author":"JF Gallegos-Orozco","year":"2012","unstructured":"Gallegos-Orozco JF, Foxx-Orenstein AE, Sterler SM, Stoa JM. Chronic constipation in the elderly. Am J Gastroenterol. 2012;107(1):18\u201325.","journal-title":"Am J Gastroenterol."},{"key":"850_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.nbd.2016.07.007","volume":"107","author":"E Zenaro","year":"2017","unstructured":"Zenaro E, Piacentino G, Constantin G. The blood\u2013brain barrier in Alzheimer\u2019s disease. Neurobiol Dis. 2017;107:41\u201356.","journal-title":"Neurobiol Dis."},{"issue":"1","key":"850_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/0271678X16679420","volume":"37","author":"F Erdo","year":"2017","unstructured":"Erdo F, Denes L, de Lange E. Age-associated physiological and pathological changes at the blood\u2013brain barrier: a review. J Cereb Blood Flow Metab. 2017;37(1):4\u201324.","journal-title":"J Cereb Blood Flow Metab."},{"key":"850_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1750-1326-8-38","volume":"8","author":"F Marques","year":"2013","unstructured":"Marques F, Sousa JC, Sousa N, Palha JA. Blood\u2013brain-barriers in aging and in Alzheimer\u2019s disease. Mol Neurodegener. 2013;8:38.","journal-title":"Mol Neurodegener."},{"issue":"2","key":"850_CR10","first-page":"114","volume":"5","author":"R Oakley","year":"2014","unstructured":"Oakley R, Tharakan B. Vascular hyperpermeability and aging. Aging Dis. 2014;5(2):114\u201325.","journal-title":"Aging Dis."},{"issue":"2","key":"850_CR11","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.neuron.2014.12.032","volume":"85","author":"A Montagne","year":"2015","unstructured":"Montagne A, Barnes SR, Sweeney MD, Halliday MR, Sagare AP, Zhao Z, et al. Blood\u2013brain barrier breakdown in the aging human hippocampus. Neuron. 2015;85(2):296\u2013302.","journal-title":"Neuron"},{"issue":"7","key":"850_CR12","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1089\/jpm.2014.0362","volume":"18","author":"J Bull","year":"2015","unstructured":"Bull J, Wellman CV, Israel RJ, Barrett AC, Paterson C, Forbes WP. Fixed-dose subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation: results of a randomized, placebo-controlled study and open-label extension. J Palliat Med. 2015;18(7):593\u2013600.","journal-title":"J Palliat Med."},{"issue":"4","key":"850_CR13","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1097\/00000542-199710000-00008","volume":"87","author":"DB Murphy","year":"1997","unstructured":"Murphy DB, Sutton JA, Prescott LF, Murphy MB. Opioid-induced delay in gastric emptying: a peripheral mechanism in humans. Anesthesiology. 1997;87(4):765\u201370.","journal-title":"Anesthesiology"},{"key":"850_CR14","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2147\/TCRM.S80749","volume":"12","author":"W Siemens","year":"2016","unstructured":"Siemens W, Becker G. Methylnaltrexone for opioid-induced constipation: review and meta-analyses for objective plus subjective efficacy and safety outcomes. Ther Clin Risk Manag. 2016;12:401\u201312.","journal-title":"Ther Clin Risk Manag."},{"issue":"1","key":"850_CR15","first-page":"39","volume":"7","author":"N Slatkin","year":"2009","unstructured":"Slatkin N, Thomas J, Lipman AG, Wilson G, Boatwright ML, Wellman C, et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol. 2009;7(1):39\u201346.","journal-title":"J Support Oncol."},{"issue":"2","key":"850_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/1098-2299(200006)50:2<133::AID-DDR1>3.0.CO;2-8","volume":"50","author":"CS Yuan","year":"2000","unstructured":"Yuan CS, Foss JF. Methylnaltrexone: investigation of clinical applications. Drug Dev Res. 2000;50(2):133\u201341.","journal-title":"Drug Dev Res."},{"issue":"5","key":"850_CR17","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.jpain.2010.11.008","volume":"12","author":"E Michna","year":"2011","unstructured":"Michna E, Blonsky ER, Schulman S, Tzanis E, Manley A, Zhang H, et al. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. J Pain. 2011;12(5):554\u201362.","journal-title":"J Pain."},{"issue":"6","key":"850_CR18","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/papr.12535","volume":"17","author":"R Rauck","year":"2017","unstructured":"Rauck R, Slatkin NE, Stambler N, Harper JR, Israel RJ. Randomized, double-blind trial of oral methylnaltrexone for the treatment of opioid-induced constipation in patients with chronic noncancer pain. Pain Pract. 2017;17(6):820\u20138.","journal-title":"Pain Pract."},{"issue":"22","key":"850_CR19","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1056\/NEJMoa0707377","volume":"328","author":"J Thomas","year":"2008","unstructured":"Thomas J, Karver S, Cooney GA, Chamberlain BH, Watt CK, Slatkin NE, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;328(22):2332\u201343.","journal-title":"N Engl J Med."},{"issue":"3","key":"850_CR20","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3109\/00952998709001515","volume":"13","author":"L Handelsman","year":"1987","unstructured":"Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse. 1987;13(3):293\u2013308.","journal-title":"Am J Drug Alcohol Abuse."},{"issue":"4","key":"850_CR21","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/j.1526-4637.2003.03038.x","volume":"4","author":"DT Cowan","year":"2003","unstructured":"Cowan DT, Wilson-Barnett J, Griffiths P, Allan LG. A survey of chronic noncancer pain patients prescribed opioid analgesics. Pain Med. 2003;4(4):340\u201351.","journal-title":"Pain Med."},{"issue":"11","key":"850_CR22","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1016\/j.clinthera.2014.10.013","volume":"36","author":"SE Redding","year":"2014","unstructured":"Redding SE, Liu S, Hung WW, Boockvar KS. Opioid interruptions, pain, and withdrawal symptoms in nursing home residents. Clin Ther. 2014;36(11):1555\u201363.","journal-title":"Clin Ther."},{"key":"850_CR23","unstructured":"Relistor [package insert]. Bridgewater, NJ: Salix Pharmaceuticals; 2018."},{"issue":"1","key":"850_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/2042098615615472","volume":"7","author":"AH Lavan","year":"2016","unstructured":"Lavan AH, Gallagher P. Predicting risk of adverse drug reactions in older adults. Ther Adv Drug Saf. 2016;7(1):11\u201322.","journal-title":"Ther Adv Drug Saf."}],"updated-by":[{"DOI":"10.1007\/s40266-021-00860-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:00:00Z","timestamp":1619136000000}}],"container-title":["Drugs &amp; Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-021-00850-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-021-00850-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-021-00850-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T18:58:27Z","timestamp":1627671507000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-021-00850-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,31]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["850"],"URL":"https:\/\/doi.org\/10.1007\/s40266-021-00850-w","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,31]]},"assertion":[{"value":"28 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2021","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40266-021-00860-8","URL":"https:\/\/doi.org\/10.1007\/s40266-021-00860-8","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Salix Pharmaceuticals, a division of Bausch Health US, LLC, Bridgewater, NJ, USA, which has licensed the rights to develop and commercialize Relistor<sup>\u00ae<\/sup> from Progenics Pharmaceuticals, Inc., New York, NY, USA, a wholly owned subsidiary of Lantheus Holdings, Inc., North Billerica, MA, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Solomon S. Liao has no disclosures to report; Neal E. Slatkin is an employee and shareholder of Salix Pharmaceuticals, a division of Bausch Health US, LLC; and Nancy Stambler is a full-time employee of Progenics Pharmaceuticals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Each study received local or central Institutional Review Board approval and followed good clinical practice and Declaration of Helsinki principles.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Each study obtained pre-enrollment patient written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"The datasets generated and\/or analyzed during the current study are not publicly available at this time due to the proprietary nature of this information. Requests for additional information should be made to the corresponding author.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing statement"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors made substantial contributions to conception, design, and interpretation of the analysis; participated in revising the manuscript critically for important intellectual content; and provided final approval of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}